

POWER OF ATTORNEY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

POWER OF ATTORNEY BY ASSIGNEE  
AND EXCLUSION OF INVENTOR(S) UNDER 37 C.F.R. 3.71  
WITH STATEMENT UNDER 37 C.F.R. 3.73(b)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The undersigned assignee of the patents and patent applications listed on Attachment A, hereby appoints Practitioners of Jones Day associated with Customer Number 20583, which mailing address is Jones Day, 222 East 41st Street, New York, New York 10017, as its attorneys to prosecute these applications and to transact all business in the United States Patent and Trademark Office connected therewith, said appointment to be to the exclusion of the inventors and their attorney(s) in accordance with the provisions of 37 C.F.R. 3.71.

Please direct all correspondence for this application to Customer no. 20583.

Statement Under 37 C.F.R. 3.73(b)

L'UNIVERSITÉ MONTPELLIER II states that it is:

- ☐ the assignee of the entire right, title, and interest; or  
☒ an assignee of less than the entire right, title and interest.

in the patent applications/patent identified above by virtue of:

- ☒ An assignment agreement dated March 4, 2009. The assignment agreement was recorded in the United States Patent and Trademark Office on May 6, 2009 at Reel 022644, Frame 0923, or for which a copy thereof is attached.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

ASSIGNEE: L'UNIVERSITÉ MONTPELLIER II

Date: 24/05/2009 Signature: \_\_\_\_\_

Typed Name: DANIELE HERIN

Position/Title: PRESIDENT



# Attachment A

Ames Data Call	Product No.	Initial Ref. No.	Date Retired/PROV	Inventor	Serial No.	Filed	Title
417431-999016	11874-016-999	1017 US PROV	PROV	Gosselin, G. Sommadossi, J.-P. Mossa, A. Piera, C. Benzoni-Pinel, S. Lecourt, D. LaColla, P.	60292,351	6/28/02	2' and 3' Nucleoside Prodrugs for Treating Hepatitis C Virus
417431-999016	11874-016-999	1017 US	11874-016-999 11874-016-999 11874-120-999	LaColla, P. Sommadossi, J.-P. Gosselin, G. Storer, R.	10609,288	6/27/03	2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417431-999047	11874-047-999	1017 US CON 1	CON of 11874-016-999	Gosselin, G. Sommadossi, J.-P. LaColla, P.	11005,471	12/6/04	2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417431-999048	11874-048-999	1017 US CON 2	CON of 11874-016-999	Gosselin, G. Sommadossi, J.-P.	11005,442	12/6/04	2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417431-999049	11874-049-999	1017 US CON 3	CON of 11874-016-999	Gosselin, G. Sommadossi, J.-P.	11005,466	12/6/04	2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417431-999050	11874-050-999	1017 US CON 4	CON of 11874-016-999	Gosselin, G. Sommadossi, J.-P.	11005,440	12/6/04	2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417431-999051	11874-051-999	1017 US CON 5	CON of 11874-016-999	Gosselin, G. Sommadossi, J.-P.	11005,443	12/6/04	2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417431-999052	11874-052-999	1017 US CON 6	CON of 11874-016-999	Gosselin, G. Sommadossi, J.-P.	11005,446	12/6/04	2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417431-999053	11874-053-999	1017 US CON 7	CON of 11874-016-999	Gosselin, G. Sommadossi, J.-P.	11005,472	12/6/04	2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417431-999054	11874-054-999	1017 US CON 8	CON of 11874-016-999	Gosselin, G. Sommadossi, J.-P.	11005,444	12/6/04	2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections

Jones Day, CMI	Desktop No.	Index Ref. No.	Type Related	Investigator	Serial No.	Filed	Title
417451-999035	11874-035-488	1018 US PROV	PROV	Storer, R. Gosselin, G. Sommadossi, J.-P. Moussa, A. LaColla, P.	60392,530	6/2/02	Modified 2' and 3' Nucleoside Prodrugs for Treating Hepatitis C Virus
417451-999035	11874-035-599	1018 US		Storer, R. Gosselin, G. LaColla, P.	10668,907	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999036	11874-036-999	1018 US CON 1	CON of 11874-035-999	LaColla, P. Storer, R. Gosselin, G. Sommadossi, J.-P.	11005,445	12/6/04	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999037	11874-037-999	1018 US CON 2	CON of 11874-035-999	LaColla, P. Storer, R. Gosselin, G. Sommadossi, J.-P.	11005,473	12/6/04	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999038	11874-038-999	1018 US CON 3	CON of 11874-035-999	Storer, R. Gosselin, G. LaColla, P. Sommadossi, J.-P.	11005,468	12/6/04	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999039	11874-039-999	1018 US CON 4	CON of 11874-035-999	Storer, R. Gosselin, G. LaColla, P. Sommadossi, J.-P.	11005,467	12/6/04	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999040	11874-040-999	1018 US CON 5	CON of 11874-035-999	LaColla, P. Storer, R. Gosselin, G. Sommadossi, J.-P.	11005,470	12/6/04	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999041	11874-041-999	1018 US CON 6	CON of 11874-035-999	Storer, R. Gosselin, G. LaColla, P. Sommadossi, J.-P.	11005,447	12/6/04	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999042	11874-042-999	1018 US CON 7	CON of 11874-035-999	Storer, R. Gosselin, G. LaColla, P. Sommadossi, J.-P.	11005,441	12/6/04	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections

Index Data CMI	Product No.	Ident. Ref. No.	Type Retained	Inventor	Serial No.	Filed	Title
417451-999063	11874-003-999	1018 US CON 8	CON of 11874-003-999	La Colla, P. Storer, R. Gosselin, G. Sommadossi, J.-P.	11/003,469	12/6/04	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999100	11874-100-999	1018 US DIV	DIV of 11874- 003-999	La Colla, P. Storer, R. Gosselin, G. Sommadossi, J.-P.	12/31,868	6/2/08	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999026	11874-026-999	1031 US	11874-015-888 11874-130-888	Sommadossi, J.-P. La Colla, P. Gosselin, G.	10/607,909	6/27/03	2'-C-Methyl-3'-O-4'-Value Ester Ribonucleosyl Cytidine for Treatment of Flaviviridae Infections
417451-999086	11874-006-999	1031 US CON 1	CON of 11874-006-999	Sommadossi, J.-P. Gosselin, G. La Colla, P.	11/516,928	9/6/06	2'-C-Methyl-3'-O-4'-Value Ester Ribonucleosyl Cytidine for Treatment of Flaviviridae Infections
417451-488077	11874-077-488	1040 US PROV	PROV	Gosselin, G. Seeth, F. La Colla, P. Storer, R. Duker, D. Leroy, F.	60/582,182	6/23/04	5-Azet-7-Desoxyribose Derivatives for Treating Flaviviridae
417451-999077	11874-077-999	1040 US	11874-077-888	Gosselin, G. Seeth, F. La Colla, P. Storer, R. Duker, D. Leroy, F.	11/164,498	6/23/05	5-Azet-7-Desoxyribose Derivatives for Treating Flaviviridae